Top

Published in:

01-02-2008 | Brief Report

Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker

Authors: Claudio Celentano, Federico Prefumo, Elena di Vera, Annamaria Iannicco, Davide Pio Gallo, Marco Liberati

Published in: Pediatric Nephrology | Issue 2/2008

Abstract

We report on a case of fetal toxicity due to maternal treatment with olmesartan medoxomil. At 29 weeks’ gestation, oligohydramnios was found, although the fetus had normal kidneys on ultrasound evaluation. Withdrawal of olmesartan medoxomil, maternal rehydration, and a single dose of furosemide reversed the renal impairment. After term delivery, the neonate was confirmed to have normal renal function. The case suggested that fetal renal impairment due to olmesartan medoxomil may be reversible.

Cooke CE, Fatodu H (2006) Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm 12:649–655PubMed

Pryde PG, Sedman AB, Nugent CE, Barr M Jr (1993) Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3:1575–1582PubMed

Saji H, Yamanaka M, Hagiwara A, Ijiri R (2001) Losartan and fetal toxic effects. Lancet 357:363PubMedCrossRef

Alwan S, Polifka JE, Friedman JM (2005) Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73:123–130PubMedCrossRef

Daikha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R (2006) Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol 21:729–732PubMedCrossRef

Quan A (2006) Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 82:23–28PubMedCrossRef

Prandota J (2001) Clinical pharmacology of furosemide in children: a supplement. Am J Ther 8:275–289PubMedCrossRef

Kelly TF, Moore TR, Brace RA (1993) Hemodynamic and fluid responses to furosemide infusion in the ovine fetus. Am J Obstet Gynecol 168:260–268PubMed

Flack NJ, Sepulveda W, Bower S, Fisk NM (1995) Acute maternal hydration in third-trimester oligohydramnios: effects on amniotic fluid volume, uteroplacental perfusion, and fetal blood flow and urine output. Am J Obstet Gynecol 173:1186–1191PubMedCrossRef

10.

Iura T, Makinoda S, Fujita S, Matsuzawa S, Waseda T, Oshima K, Tomizawa H (2005) Analysis of the renal artery hemodynamics in normal fetuses using the color Doppler method. Fetal Diagn Ther 20:86–90PubMedCrossRef

11.

Barr M (1994) Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 50:399–409PubMedCrossRef

12.

Spence SG, Allen HL, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS (1995) Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 51:367–382PubMedCrossRef

Title: Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker
Authors: Claudio Celentano
Federico Prefumo
Elena di Vera
Annamaria Iannicco
Davide Pio Gallo
Marco Liberati
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 2/2008
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-007-0618-8

At a glance: The STEP trials

Springer Medicine

Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Pitfalls in studies of children with monosymptomatic nocturnal enuresis

Dialysate leakage into pericardium in an infant on long-term peritoneal dialysis

Reliability of different expert systems for profiling proteinuria in children with kidney diseases

Influence of N-acetylcysteine on renal toxicity of cadmium in rats

Clinical course and NPHS2 analysis in patients with late steroid-resistant nephrotic syndrome

Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity